The Impact of Antioxidant Diets, Nutraceuticals, and Physical Activity Interventions in the Prevention of Cardiometabolic Diseases: An Overview
Abstract
Hippocrates – Father of Medicine (ca 460-370 B.C.) – endorsed the curative effects of foods; he said: “Leave your drugs in the chemist’s pot if you can heal the patient with food”. This review focuses on the management of cardiometabolic diseases (CMDs) with nutraceuticals and antioxidant diets such as Allium sativum, turmeric, soybean, peptides, phytosterols, resveratrol, polyphenolic substances etc. CMDs are a cluster of conditions linked to altered fat and carbohydrate metabolism as well as macro- and micro-vascular problems. CMDs cause severe pathophysiological and metabolic alterations in the body, resulting in the occurrence of chronic diseases like atherosclerosis, coronary heart disease and stroke, neurodegenerative ailments, fatty liver, kidney malfunction, hypercholesterolaemia, hyperlipidaemia, insulin resistance and some cancers, consequently imposing a very high economic burden on the healthcare costs. Currently used pharmacotherapies are not only expensive but also are associated with undesirable adverse events. Thus, there is an urgent need for affordable, cost-effective and alternative safe therapies for the prevention and management of CMDs. Holistic approaches targeted for health promotion and prevention of CMDs include the intake of antioxidant-rich diets, anti-inflammation wholesome foods and moderate physical activity (about 30 min/day). Such strategies will not only prevent obesity-related CMDs, type 2 diabetes mellitus (T2DM), coronary heart disease and stroke, but also will improve the quality of patient’s life and consequently reduce healthcare burdens. Nutraceuticals and probiotics exhibit anti-inflammation, anti-aging, anti-obesity and anti-diabetic effects, thereby reducing the adverse health risks associated with CMDs. Antioxidants protect cell membranes and DNA from excessive free radicals, which contribute to CMD related diseases. Physical exercise along with dietary interventions helps to mitigate oxidative stress, improve blood triglyceride levels, increase HDL-cholesterol and reduce LDL-cholesterol and reverse the biological markers associated with CMDs. Many studies have provided robust scientific evidence and demonstrated links between dietary interventions, nutraceuticals, probiotics, wholesome foods and physical activity for the prevention of CMDs. The major limitations in promoting nonpharmacological therapies for health and well-being benefits are a lack of public awareness and a paucity of clinical nutrition instruction for medical students on the merits of complementary methods for the prevention and management of CMDs. The goals of this review are to provide up-to-date knowledge about selected nutraceuticals, wholesome foods and physical activity in the prevention of CMDs and the underlying mechanisms associated with each intervention, which will ultimately improve patient’s quality of life and assist in reducing healthcare costs globally.
References
Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes 2010;2:180–93.
Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433–8.
Kirk EP, Klein S. Pathogenesis and pathophysiology of the cardiometabolic syndrome. J Clinical Hypertension 2009; 11:761. doi:10.1111/J.1559-4572.2009.00054.X.
World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:i-xii, 1-253.
Friend A, Craig L, Turner S. The prevalence of metabolic syndrome in children: a systematic review of the literature. Metab Syndr Relat Disord 2013;11:71–80.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart Disease and Stroke Statistics--2013 update: a report from the American Heart Association. Circulation 2013;127. doi:10.1161/CIR.0B013E31828124AD.
Castro JP, El-Atat FA, McFarlane SI, Aneja A, Sowers JR. Cardiometabolic syndrome: Pathophysiology and treatment. Curr Hypertens Rep 2003;5:393–401.
Arnold SV, Inzucchi SE, Echouffo-Tcheugui JB, Tang F, Lam CSP, Sperling LS, et al. Understanding contemporary use of thiazolidinediones. Circ Heart Fail 2019;12. doi:10.1161/CIRCHEARTFAILURE.118.005855.
Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud 2014 Fall-Winter;11(3-4):202-30.
Golomb BA, Evans MA. Statin adverse effects. Am J Cardiovascular Drugs 2008;8:373–418.
Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. Diabetes Care 2004;27:256–63.
Rizos C, Elisaf M, Mikhailidis D, Liberopoulos E. How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf 2009;8:15–32.
Brunton LL, Hilal-Dandan R, Knollmann BC. Renin and Angiotensin. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw Hill; 2017.
Osborn LJ, Claesen J, Brown JM. Microbial flavonoid metabolism: A cardiometabolic disease perspective. Annu Rev Nutr 2021 Oct 11;41:433-54.
Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: A comprehensive review. Circulation 2016;133:187–225.
Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2009;4:113–9.
Hallal PC, Cordeira K, Knuth AG, Mielke GI, Victora CG. Ten-year trends in total physical activity practice in Brazilian adults: 2002-2012. J Phys Act Health 2014;11:1525–30.
Bhurosy T, Jeewon R. Overweight and obesity epidemic in developing countries: A problem with diet, physical activity, or socioeconomic status? The Scientific World J 2014; 2014:1–7.
Archer E, Shook RP, Thomas DM, Church TS, Katzmarzyk PT, Hébert JR, et al. 45-Year trends in women’s use of time and household management energy expenditure. PLoS One 2013;8:e56620. doi:10.1371/journal.pone.0056620.
Kaur G, Mukundan S, Wani V, Kumar SM. Nutraceuticals in the management and prevention of metabolic syndrome. Austin J Pharmacol Ther 2015;1063. ISSN: 2373-6208.
Giudetti AM, Micioni Di Bonaventura MV, Ferramosca A, Longo S, Micioni Di Bonaventura E, Friuli M, et al. Brief daily access to a cafeteria‐style diet impairs hepatic metabolism even in the absence of excessive body weight gain in rats. The FASEB Journal 2020;34:9358–71.
Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018; 20:12. doi:10.1007/s11906-018-0812-z.
Vergara D, Scoditti E, Aziz AA, Giudetti AM. Editorial: Dietary antioxidants and metabolic diseases. Front Nutr 2021;8. doi:10.3389/fnut.2021.617859.
Khorasani S, Danaei M, Mozafari MR. Nanoliposome technology for the food and nutraceutical industries. Trends Food Sci Technol 2018;79:106–15.
Das L, Bhaumik E, Raychaudhuri U, Chakraborty R. Role of nutraceuticals in human health. J Food Sci Technol 2012;49:173–83.
Larussa T, Imeneo M, Luzza F. Potential role of nutraceutical compounds in inflammatory bowel disease. World J Gastroenterol 2017; 23:2483. doi:10.3748/wjg.v23.i14.2483.
Lee E-S, Song E-J, Nam Y-D, Lee S-Y. Probiotics in human health and disease: From nutribiotics to pharmabiotics. J Microbiology 2018;56:773–82.
Shinde N, Bangar B, Deshmukh S, Kumbhar P. Nutraceuticals: A review on current status. J Pharm and Tech 2014;7. ISSN:0974-3618.
Gonçalves RFS, Martins JT, Duarte CMM, Vicente AA, Pinheiro AC. Advances in nutraceutical delivery systems: From formulation design for bioavailability enhancement to efficacy and safety evaluation. Trends Food Sci Technol 2018;78:270–91.
Natarajan TD, Ramasamy JR, Palanisamy K. Nutraceutical potentials of synergic foods: a systematic review. J Ethnic Foods 2019; 6:27. doi:10.1186/s42779-019-0033-3.
Paolino D, Mancuso A, Cristiano MC, Froiio F, Lammari N, Celia C, et al. Nanonutraceuticals: The new frontier of supplementary food. Nanomaterials 2021;11:1–20.
Jain S, Buttar HS, Chintameneni M, Kaur G. Prevention of cardiovascular diseases with anti-inflammatory and anti- oxidant nutraceuticals and herbal products: An overview of pre-clinical and clinical studies. Recent Pat Inflamm Allergy Drug Discov 2018;12:145–57.
Ramaa CS, Shirode AR, Mundada AS, Kadam VJ. Nutraceuticals--an emerging era in the treatment and prevention of cardiovascular diseases. Curr Pharm Biotechnol 2006 Feb;7(1):15-23.
Li JJ, Dou KF, Zhou ZG, Zhao D, Ye P, Zhao JJ, et al. Role of omega-3 fatty acids in the prevention and treatment of cardiovascular diseases: A consensus statement from the Experts’ Committee of National Society of Cardiometabolic Medicine. Front Pharmocol 2022;13:5216. doi:10.3389/FPHAR.2022.1069992/BIBTEX.
Lee KW, Lip GYH. The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease. QJM 2003; 96:465–80.
Bhatnagar D, Durrington PN. Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. Int J Clin Pract 2003;57:305–14.
Richter WO. Long-chain omega-3 fatty acids from fish reduce sudden cardiac death in patients with coronary heart disease. Europ J Med Res 2003;8:332–6.
Hoang T, Kim J. Comparative effect of statins and omega-3 supplementation on cardiovascular events: meta-analysis and network meta-analysis of 63 randomized controlled trials including 264,516 participants. Nutrients 2020 Jul 25;12(8):2218. doi: 10.3390/nu12082218.
Backes J, Anzalone D, Hilleman D, Catini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis 2016;15. doi:10.1186/S12944-016-0286-4.
Rissanen T, Voutilainen S, Nyyssönen K, Lakka TA, Salonen JT. Fish oil–derived fatty acids, docosahexaenoic acid and docosapentaenoic acid, and the risk of acute coronary events. Circulation 2000;102:2677–9.
Stevinson C. Garlic for treating hypercholesterolemia. Ann Intern Med 2000;133:420. doi:10.7326/0003-4819-133-6-200009190-00009.
Sobenin IA, Pryanishnikov VV, Kunnova LM, Rabinovich YA, Martirosyan DM, Orekhov AN. The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease. Lipids Health Dis 2010;9. doi:10.1186/1476-511X-9-119.
Sangouni AA, Alizadeh M, Jamalzehi A, Hosseinzadeh M, Parastouei K. Garlic supplementation improves intestinal transit time, lipid accumulation product and cardiometabolic indices in subjects with metabolic syndrome: A randomized controlled trial. Phytother Res 2023 Jun;37(6):2305-14.
Panyod S, Wu WK, Chen PC, Chong KV, Yang YT, Chuang HL, et al. Atherosclerosis amelioration by allicin in raw garlic through gut microbiota and trimethylamine-N-oxide modulation. NPJ Biofilms and Microbiomes 2022;8(1):1–13.
Kim Y, Je Y. Dietary fibre intake and mortality from cardiovascular disease and all cancers: A meta-analysis of prospective cohort studies. Arch Cardiovasc Dis 2016;109:39–54.
Sanders TA, Dean TS, Grainger D, Miller GJ, Wiseman H. Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor β1 concentrations and hemostatic risk factors for coronary heart disease in healthy subjects. Am J Clin Nutr 2002;76:373–7.
Jenkins DJ, Kendall CW, Jackson C-JC, Connelly PW, Parker T, Faulkner D, et al. Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. Am J Clin Nutr 2002;76:365–72.
Kassaian N, Feizi A, Aminorroaya A, Amini M. Probiotic and synbiotic supplementation could improve metabolic syndrome in prediabetic adults: A randomized controlled trial. Diabetes Metab Syndr 2019;13:2991–6.
Cobos Á, Díaz O. ‘Superfoods’: Reliability of the information for consumers available on the Web. Foods 2023;12:546. doi:10.3390/FOODS12030546/S1.
Mahdavi-Roshan M, Nasrollahzadeh J, Zadeh AM, Zahedmehr A. Does garlic supplementation control blood pressure in patients with severe coronary artery disease? A clinical trial study. Iran Red Crescent Med J 2016; 18:23871. doi:10.5812/IRCMJ.23871.
Ashraf R, Aamir K, Shaikh AR, Ahmed T. Effects of garlic on dyslipidemia in patients with type 2 diabetes mellitus. J Ayub Med Coll Abbottabad 2005 Jul-Sep;17(3):60-4.
Kojuri J, Vosoughi AR, Akrami M. Effects of Anethum graveolens and garlic on lipid profile in hyperlipidemic patients. Lipids Health Dis 2007;6. doi:10.1186/1476-511X-6-5.
Said A, Buendia A, Gabriel J, Rojas J, García-Arroyo F, Emiliano O, et al. Antioxidant and anti-inflammatory effects of allicin in the kidney of an experimental model of metabolic syndrome. Peer J 2023;11: e16132. doi:10.7717/PEERJ.16132.
Charles W, Fibiol D, Frpharms F, London E, York N, St P, et al. Trease and Evans’ Pharmacognosy. London, UK: Saunders Ltd; 2009.
Li M, Yun W, Wang G, Li A, Gao J, He Q. Roles and mechanisms of garlic and its extracts on atherosclerosis: A review. Front Pharmacol 2022;13:4093. doi:10.3389/FPHAR.2022.954938/BIBTEX.
Matsuura H. Saponins in garlic as modifiers of the risk of cardiovascular disease. J Nutr 2001; 131:1000S-5S.
Bazzano LA, He J, Ogden LG, Loria CM, Whelton PK. Dietary fibre intake and reduced risk of coronary heart disease in US men and women. Arch Intern Med 2003;163:1897. doi:10.1001/archinte.163.16.1897.
Pereira MA, O’Reilly E, Augustsson K, Fraser GE, Goldbourt U, Heitmann BL, et al. Dietary fibre and risk of coronary heart disease. Arch Intern Med 2004;164:370. doi:10.1001/archinte.164.4.370.
Rangari DV. Pharmacognosy & Phytochemistry. vol. 2. Nashik, India: Career Publication; 2003.
Lupton JR, Turner ND. Dietary fibre and coronary disease: Does the evidence support an association? Curr Atheroscler Rep 2003;5:500–5.
Gunashekar DR, Singh RB, Niaz MA, Shewale AR, Takahashi T, Chauhan AK, et al. Chapter 6 - Dietary fibre and risk of cardiovascular diseases. In: Samaan RA, editor. Dietary Fiber for the Prevention of Cardiovascular Disease. Cambridge (MA): Academic Press; 2017, p. 91–120.
Feder D, Fonseca FLA. Chapter 2 - The mechanism of fibre effects on insulin resistance. In: Samaan RA, editor. Dietary Fiber for the Prevention of Cardiovascular Disease. Cambridge (MA): Academic Press; 2017, p. 23–33.
Hasler CM. The cardiovascular effects of soy products. J Cardiovasc Nurs 2002 Jul;16(4):50-63; quiz 75-6.
Hermansen K, Dinesen B, Hoie LH, Morgenstern E, Gruenwald J. Effects of soy and other natural products on LDL:HDL ratio and other lipid parameters: A literature review. Adv Ther 2003;20:50–78.
Seely S. Possible connection between milk and coronary heart disease: the calcium hypothesis. Med Hypotheses 2000;54:701–3.
Palloshi A, Fragasso G, Piatti P, Monti LD, Setola E, Valsecchi G, et al. Effect of oral l-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. Am J Cardiol 2004;93:933–5.
Kopp-Hoolihan L. Prophylactic and therapeutic uses of probiotics. J Am Diet Assoc 2001;101:229–41.
Kaur IP, Chopra K, Saini A. Probiotics: potential pharmaceutical applications. European J Pharmaceut Sci 2002;15:1–9.
Davani-Davari D, Negahdaripour M, Karimzadeh I, Seifan M, Mohkam M, Masoumi S, et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods 2019; 8:92. doi:10.3390/foods8030092.
Buttar HS. Healthful foods and lifestyle modifications are the best cost-effective strategies for the prevention of cardiovascular and cardiometabolic diseases. Scr Med 2021;52 Suppl 1:S4.
Usman, Hosono A. Effect of administration of Lactobacillus gasseri on serum lipids and fecal steroids in hypercholesterolemic rats. J Dairy Sci 2000;83:1705–11.
Agerholm-Larsen L, Raben A, Haulrik N, Hansen A, Manders M, Astrup A. Effect of 8- week intake of probiotic milk products on risk factors for cardiovascular diseases. Eur J Clin Nutr 2000;54:288–97.
Law M. Plant sterol and stanol margarines and health. BMJ 2000;320:861–4.
Shrapnel B, Simons L. Plant sterols and blood cholesterol: insights from an expert roundtable. Curr Ther (Seaforth) 2022;42(3):45-8.
Cater NB. Plant stanol ester: Review of cholesterol-lowering efficacy and implications for coronary heart disease risk reduction. Prev Cardiol 2000;3:121–30.
Lichtenstein AH, Deckelbaum RJ. Stanol/sterol ester–containing foods and blood cholesterol levels. Circulation 2001;103:1177–9.
Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans 2017;45:1105–15.
[78] Mozaffarian D, Wu JHY. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58:2047–67.
Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O’Neill LAJ, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007;21:325–32.
Durak I, Kavutcu M, Aytaç B, Avci A, Devrim E, Özbek H, et al. Effects of garlic extract consumption on blood lipid and oxidant/antioxidant parameters in humans with high blood cholesterol. JNutr Biochem 2004;15:373–7.
Ried K. Garlic lowers blood pressure in hypertensive individuals, regulates serum cholesterol, and stimulates immunity: An updated meta-analysis and review. J Nutr 2016;146:389S-396S.
Kang SA, Shin HJ, Jang KH, Choi SE, Yoon KA, Kim JS, et al. Effect of garlic on serum lipids profiles and leptin in rats fed high fat diet. Prev Nutr Food Sci 2006;11:48–53.
Krishnamurthy VMR, Wei G, Baird BC, Murtaugh M, Chonchol MB, Raphael KL, et al. High dietary fibre intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int 2012;81:300–6.
Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. Nature 2016;535:56–64.
Weickert MO, Pfeiffer AFH. Metabolic effects of dietary fibre consumption and prevention of diabetes. J Nutr 2008;138:439–42.
Omoni AO, Aluko RE. Soybean foods and their benefits: potential mechanisms of action. Nutr Rev 2005; 63:272–83.
Gu Y, Wu J. The potential of antioxidative and anti-inflammatory peptides in reducing the risk of cardiovascular diseases. Curr Opin Food Sci 2016;8:25–32.
Olas B. Probiotics, prebiotics and symbiotic Promising strategy in prevention and treatment of cardiovascular diseases? Int J Mol Sci 2020;21:1–15.
de Domenico S, Giudetti AM. Nutraceutical intervention in ageing brain. JGG 2017;65:79–92.
Griffiths K, Aggarwal B, Singh R, Buttar H, Wilson D, de Meester F. Food antioxidants and their anti-Inflammatory properties: A potential role in cardiovascular diseases and cancer prevention. Diseases 2016; 4:28. doi:10.3390/diseases4030028.
Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev 2010; 4:118. doi:10.4103/0973-7847.70902.
Liu Z, Ren Z, Zhang J, Chuang CC, Kandaswamy E, Zhou T, et al. Role of ROS and nutritional antioxidants in human diseases. Front Physiol 2018;9. doi:10.3389/fphys.2018.00477.
Bawa AS, Farhath K. Hotracooticals: Mechanism of action. Indian Food Industry 2003;22:44–51.
Ignarro L, Balestrleri M, Napoli C. Nutrition, physical activity, and cardiovascular disease: An update. Cardiovasc Res 2007;73:326–40.
Rao AV, Agarwal S. Role of antioxidant lycopene in cancer and heart disease. J Am Coll Nutr 2000;19:563–9.
Arab L, Steck S. Lycopene and cardiovascular disease. Am J Clin Nutr 2000;71:1691S-1695S.
Vita JA. Polyphenols and cardiovascular disease: effects on endothelial and platelet function. Am J Clin Nutr 2005;81:292S-297S.
Manikandan R, Beulaja M, Arulvasu C, Sellamuthu S, Dinesh D, Prabhu D, et al. Synergistic anticancer activity of curcumin and catechin: An in vitro study using human cancer cell lines. Microsc Res Tech 2012;75:112–6.
Sak K. Site-specific anticancer effects of dietary flavonoid quercetin. Nutr Cancer 2014;66:177–93.
Vergara D, Scoditti E, Aziz AA, Giudetti AM. Editorial: Dietary antioxidants and metabolic diseases. Front Nutr 2021;8. doi:10.3389/fnut.2021.617859.
Llaha F, Zamora-Ros R. The effects of polyphenol supplementation in addition to calorie restricted diets and/or physical activity on body composition parameters: A systematic review of randomized trials. Front Nutr 2020;7. doi:10.3389/fnut.2020.00084.
Chen X, Zhang C, Wang X, Huo S. Juglanin inhibits IL-1β-induced inflammation in human chondrocytes. Artif Cells Nanomed Biotechnol 2019;47:3614–20.
Zhou G-Y, Yi Y-X, Jin L-X, Lin W, Fang P-P, Lin X-Z, et al. The protective effect of juglanin on fructose-induced hepatitis by inhibiting inflammation and apoptosis through TLR4 and JAK2/STAT3 signaling pathways in fructose-fed rats. Biomed Pharmacother 2016 Jul;81:318-28.
Liu J, Chen L, Zhang X, Pan L, Jiang L. The protective effects of juglanin in cerebral ischemia reduce blood–brain barrier permeability via inhibition of VEGF/VEGFR2 signaling. Drug Des Devel Ther 2020;14:3165–75.
Sun J, Song L. Juglanin alleviates myocardial injury in rats with acute myocardial infarction through modulating MAPK signaling pathway. Qual Assur Saf Crops Foods 2021;13:116–22.
Folts JD. Potential health benefits from the flavonoids in grape products on vascular disease. Adv Exp Med Biol 2002;505:95-111.
Gómez-Téllez A, Sierra-Puente D, Muñoz-Gómez R, Ibarra-Pitts A, Guevara-Cruz M, Hernández-Ortega M, et al. Effects of a low-dose spirulina/turmeric supplement on cardiometabolic and antioxidant serum markers of patients with abdominal obesity. Front Nutr 2020;7. doi:10.3389/fnut.2020.00065.
D’Odorico A, Martines D, Kiechl S, Egger G, Oberhollenzer F, Bonvicini P, et al. High plasma levels of α- and β-carotene are associated with a lower risk of atherosclerosis. Atherosclerosis 2000;153:231–9.
Simon JA. Relation of ascorbic acid to coronary artery calcium: the coronary artery risk development in young adults study. Am J Epidemiol 2004;159:581–8.
Jacob K, Periago MJ, Böhm V, Berruezo GR. Influence of lycopene and vitamin C from tomato juice on biomarkers of oxidative stress and inflammation. Br J Nutr 2008;99:137–46.
Chen X, Guan X, Tang Y, Deng J, Zhang X. Effects of cocoa products intake on cardiometabolic biomarkers of type 2 diabetes patients: a systematic review and meta-analysis based on both long-term and short-term randomised controlled trials. Int J Food Sci Nutr 2022;73:571–87.
Nantz MP, Rowe CA, Bukowski JF, Percival SS. Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. Nutrition 2009;25:147–54.
Dludla P V, Nyambuya TM, Orlando P, Silvestri S, Mxinwa V, Mokgalaboni K, et al. The impact of coenzyme Q10 on metabolic and cardiovascular disease profiles in diabetic patients: A systematic review and meta-analysis of randomized controlled trials. Endocrinol Diabetes Metab 2020;3. doi:10.1002/EDM2.118.
Dashtabi A, Mazloom Z, Fararouei M, Hejazi N. Oral L-arginine administration improves anthropometric and biochemical indices associated with cardiovascular diseases in obese patients: A randomized, single blind placebo-controlled clinical trial. Res Cardiovasc Med 2015;5. doi:10.5812/CARDIOVASCMED.29419.
Tabrizi R, Tamtaji OR, Mirhosseini N, Lankarani KB, Akbari M, Heydari ST, et al. The effects of quercetin supplementation on lipid profiles and inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr 2020;60:1855–68.
Ding D, Kolbe-Alexander T, Nguyen B, Katzmarzyk PT, Pratt M, Lawson KD. The economic burden of physical inactivity: a systematic review and critical appraisal. Br J Sports Med 2017;51:1392–409.
Aune D, Norat T, Leitzmann M, Tonstad S, Vatten LJ. Physical activity and the risk of type 2 diabetes: a systematic review and dose–response meta-analysis. Eur J Epidemiol 2015;30:529–42.
Blondell SJ, Hammersley-Mather R, Veerman JL. Does physical activity prevent cognitive decline and dementia? A systematic review and meta-analysis of longitudinal studies. BMC Public Health 2014;14:510. doi:10.1186/1471-2458-14-510.
Buttar HS, Li T, Ravi N. Prevention of cardiovascular diseases: Role of exercise, dietary interventions, obesity and smoking cessation. Exp Clin Cardiol 2005;10:229–49.
Fagard RH. Physical activity, physical fitness and the incidence of hypertension. J Hypertens 2005 Feb;23(2):265-7.
Carnethon MR, Evans NS, Church TS, Lewis CE, Schreiner PJ, Jacobs DR, et al. Joint Associations of Physical Activity and Aerobic Fitness on the Development of Incident Hypertension. Hypertension 2010;56:49–55.
Pedersen BK, Saltin B. Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports 2015;25:1–72.
Kokkinos P. Physical activity, health benefits, and mortality risk. ISRN Cardiol 2012;2012:1–14.
Bielemann RM, Martinez-Mesa J, Gigante DP. Physical activity during life course and bone mass: a systematic review of methods and findings from cohort studies with young adults. BMC Musculoskelet Disord 2013; 14:77. doi:10.1186/1471-2474-14-77.
Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev 2006 Oct 18;2006(4):CD003817. doi: 10.1002/14651858.CD003817.pub3.
Williams RA, Cooper SB, Dring KJ, Hatch L, Morris JG, Sun FH, et al. Physical fitness, physical activity and adiposity: associations with risk factors for cardiometabolic disease and cognitive function across adolescence. BMC Pediatr 2022;22:1–15.
Gupta N, Crouse DL, Miah P, Takaro T. Individual physical activity, neighbourhood active living environment and mental illness hospitalisation among adults with cardiometabolic disease: a Canadian population-based cohort analysis. BMJ Open 2023;13:e067736. doi:10.1136/BMJOPEN-2022-067736.
Xu C, Zhang P, Cao Z. Cardiovascular health and healthy longevity in people with and without cardiometabolic disease: A prospective cohort study. EClinicalMedicine 2022 Mar 6;45:101329. doi: 10.1016/j.eclinm.2022.101329.
McCrorie P, Mitchell R, Macdonald L, Jones A, Coombes E, Schipperijn J, et al. The relationship between living in urban and rural areas of Scotland and children’s physical activity and sedentary levels: a country-wide cross-sectional analysis. BMC Public Health 2020; 20:304. doi:10.1186/s12889-020-8311-y.
Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity. Circulation 2016;133:187–225.
Chaput J-P, Klingenberg L, Rosenkilde M, Gilbert J-A, Tremblay A, Sjödin A. Physical activity plays an important role in body weight regulation. J Obes 2011;2011:1–11.
Bull F, Goenka S, Lambert V, Pratt M. Physical activity for the prevention of cardiometabolic disease. In: Prabhakaran D, Anand S, Gaziano TA, Mbanya JC, Wu Y, Nugent R, editors. Cardiovascular, respiratory, and related disorders. 3rd ed. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 17. Chapter 5.
Buttar HS, Li T, Ravi N. Prevention of cardiovascular diseases: Role of exercise, dietary interventions, obesity and smoking cessation. Exp Clin Cardiol 2005;10(4):229-49.
Lee LO, Grimm KJ, Spiro A, Kubzansky LD. Neuroticism, worry, and cardiometabolic risk trajectories: Findings from a 40-year study of men. J Am Heart Assoc 2022;10:e022006. doi: 10.1161/JAHA.121.022006.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).